Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Bivalent Type 1 & 3 Oral Poliomyelitis Vaccines** is Bio Farma's live-attenuated oral poliovirus vaccine for active prevention of poliomyelitis caused by poliovirus types 1 and 3. Each 0.1 mL oral dose comprises two drops containing Sabin-strain poliovirus types 1 and 3. The vaccine is supplied as a multidose oral suspension and is intended for direct oral administration; it has been evaluated in Indonesian infants, including concomitant administration with Pentabio and inactivated poliovirus vaccine. ([biofarma.co.id](https://www.biofarma.co.id/en/our-product/detail/bivalen-type-1-3-oral-poliomyelitis-vaccines))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bivalent Type 1 & 3 Oral Poliomyelitis Vaccines.